bulk drug was taken into account in each case while fixing the formulation prices?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) to (f) Information to the extent available would be collected and would be laid on the Table of the Rajya Sabha.

Price Fixation of Anti-Cancer Drugs

595. SHRI SYED RAHMAT ALI: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether Mitomycin, Adriamycin and Bleomycin Injections are Anti-cancer drugs;

(b) if so, what is the price fixed for each injection;

(c) whether it is a fact that the price of these injections are high;

(d) what steps are being taken by his Ministry to provide at least anti-cancer drugs at reasonable prices;

(e) whether it is a fact that NDPDC have recommended for price decontrol of anti-cancer drugs; and

(f) if so, what is the justification for such recommendation?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI VEERENDRA PATIL): (a) Yes, Sir.

(b) The prices of these formulations referred to as fixed under the Drugs (Prices Control) Order, 1979 are as follows:

Sl. No.	Name of the formulation	Pack size	Maximum retail price as fixed by the Government
1.	Mitomycin Inj.	2mg. vial	29.59
2.	Do.	10mg vial	131.34
3.	Adriamycin.	10mg. vial	156.63
4.	Bleomycin Inj	15mg./amp.	202.11

(c) and (d) Fair and reasonable prices for imported formulations are based under the provisions of Drugs (Prices Control) Order, 1979. In fixing such price a mark up of only 50 per cent on the landed cost of imports is allowed. In order to ensure that anti-cancer medicines are available at cheap prices, Government have granted customs duty examption on most of the anti-cancer drugs when imported into the Country in the finished form.

(e) No, Sir. National Drugs & Pharmaceuticals Development Council have recommended price control on four anti-cencer bulk drugs and their formulations.

(f) Does not arise.

Price increase of formulations

596. SHRIMATI MONIKA DAS: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) names of the products along with names of the companies who applied for increase in prices of formulations during the year 1984 and up to 30th June, 1985;

(b) what are the basis on which each manufacturer has claimed price increase;

(c) in how many cases, the price increase was allowed and to what percentage and what were their earlier prices and increased prices;

(d) how many applications are still pending alongwith the names of products and the reasons for keeping them pending;

(e) by when the decision on pending applications will be finalised;

(f) is there any time limit for disposing of the applications; and